XO Life receives 7 Million Euros for the international expansion of its health platform as an alternative to Google, Facebook and Co.

München, Deutschland, 22. August 2024 – XO Life, a leading digital health startup from Germany, has developed the ImpactMonitor™ platform, a meta-platform that provides patients with trustworthy health information, therapy monitoring as well as support and exchange with other patients. A consortium of four venture capital firms invests 7 million euros in the international expansion of the ImpactMonitor™ platform, which represents a specialized alternative to conventional searches such as on Google, Facebook, TikTok or Instagram. The lead investors are Sandwater and Grazia Equity with participation from Vi Partners and Bayern Kapital. Existing investors such as Aescuvest, Winning Mindset Ventures and Isartal Ventures are participating again.

‍

Patients have a significant need for information and communication when they receive a diagnosis or medication. 70% of patients research online at least once a week, with Google and Facebook being the first choice. However, online content is often optimized for search engines and user searches for advertisement. Only 8 out of 10 patients therefore trust online information, they feel left alone and uncertain.

“This investment will enable us to advance our technology and expand internationally. Having proven our success in the German market, we are eager to address global health challenges and bring our innovative solutions to a wider audience,” says Dr. Friderike Bruchmann, Co-Founder and CEO of XO Life.

ImpactMonitor™: Meta-platform for digital patient support

XO Life has developed a meta-platform which serves as a digital companion for patients with regard to their medications, products, therapies and diseases. The platform provides patients with verified medical information, collects patient feedback, so-called patient-reported outcomes, offers real world insights from other patients and enables exchange as well as medical support. 

Pharma and MedTech manufacturers, among other healthcare players, offer specific product and therapy spaces via the platform to their patients. TheImpactMonitor™ platform helps manufacturers and research institutions (the latter for free) to identify the needs and preferences of patients and supports the development of new patient-oriented therapies. To ensure an objective and free user experience, there is no exclusive content or sponsorship by manufacturers. Registration on the ImpactMonitor™ platform is quick, free and easy via Mac, PC or the app for iOS and Android.

7 million euros for the international expansion of the ImpactMonitor™ platform

The investment round is led by the Norwegian VC Sandwater and the German VC Grazia Equity. The Swiss VC VI Partners and the public VC Bayern Kapital are co-investors. Existing investors such as Aescuvest, Winning Mindset Ventures and Isartal Ventures as well as numerous other investors and family offices from the health and healthcare sector are also participating in this financing round.

Morten E. Iversen, Partner at Sandwater explains: "We are enthusiastic about the unique opportunities and possibilities of XO Life's meta-platform. We are convinced that the ImpactMonitor™ platform will fill an important gap in healthcare by providing comprehensive health information and patient support across Europe and beyond." 

Jochen Klüppel, Partner at Grazia Equity emphasizes: “XO Life has developed and built an impressive digital meta-platform. Backed by a strong VC consortium, the team, which has technical expertise in medicine, natural sciences and information technology and brings together talent from more than 13 nations, can take the ImpactMonitor™ platform to the next level. We are relying on the best of the best to revolutionize an entire industry!”

Arnd Kaltofen, Partner at Vi Partners, adds: "The combination of sound medical information and an intuitive platform is tailored to today's patient needs. In addition, the Impact-Monitor™ platform provides physicians, medical institutions and companies with valuable insights into the needs and preferences of users and can thus support the development of new, patient-oriented therapies." 

Markus Mrachacz, Managing Director at Bayern Kapital, says: "XO Life's intuitive platform offers patients validated medical information, and provides better insights into the questions and needs of patients to medical institutions and pharmaceutical companies. This combination makes XO Life an exciting opportunity in the digital health sector for us."

About XO Life

XO Life has created a globally unique meta-platform, the ImpactMonitor™ platform, for digital product and therapy support for patients. Patients are accompanied during their product application or therapy with verified medical and health-relevant content, record their health and therapy progress, receive personalized insights and medical support from experts and can exchange information with other patients. 

Manufacturers create their own product and therapy areas on the ImpactMonitor™ platform and offer them to their patients with their own branding, content, questions and services. By providing personalized information and continuous support during treatment, manufacturers make an important contribution to the success of treatment, treatment adherence and application safety for patients. 

XO Life works with global market leaders, SMEs and rare disease manufacturers in more than 30 indications. User engagement on the platform is 10x higher than the average digital health app and last year alone over 120,000 medical questions were answered by patients. The ImpactMonitor™ platform is now available in all European countries and languages.

‍

More links

Website: www.xo-life.com

LinkedIn: https://www.linkedin.com/company/xo-life

YouTube: https://www.youtube.com/@xo-life/featured

‍

Press Contact

Startup Communication

Raphael Auer

‍ra@startup-communication.de

Leonrodstraße 58

80636 Munich